Literature DB >> 24330157

Cerebrospinal fluid α-synuclein levels in Parkinson's disease--changed or unchanged?

H Zetterberg1, M Petzold, N Magdalinou.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24330157     DOI： 10.1111/ene.12326

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN： 1351-5101            Impact factor:   6.089


× No keyword cloud information.
  10 in total

Review 1.  Advances in Biomarker Research in Parkinson's Disease.

Authors:  Shyamal H Mehta; Charles H Adler
Journal:  Curr Neurol Neurosci Rep       Date:  2016-01       Impact factor: 5.081

2.  CSF biomarkers and clinical progression of Parkinson disease.

Authors:  Sara Hall; Yulia Surova; Annika Öhrfelt; Henrik Zetterberg; Daniel Lindqvist; Oskar Hansson
Journal:  Neurology       Date:  2014-11-19       Impact factor: 9.910

Review 3.  Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments.

Authors:  Simone Lista; Henrik Zetterberg; Bruno Dubois; Kaj Blennow; Harald Hampel
Journal:  J Neurol       Date:  2014-05-08       Impact factor: 4.849

4.  A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes.

Authors:  N K Magdalinou; R W Paterson; J M Schott; N C Fox; C Mummery; K Blennow; K Bhatia; H R Morris; P Giunti; T T Warner; R de Silva; A J Lees; H Zetterberg
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-01-14       Impact factor: 10.154

Review 5.  The Diagnostic and Differential Diagnosis Utility of Cerebrospinal Fluid α -Synuclein Levels in Parkinson's Disease: A Meta-Analysis.

Authors:  Bo Zhou; Min Wen; Wen-Feng Yu; Chun-Lin Zhang; Ling Jiao
Journal:  Parkinsons Dis       Date:  2015-07-29

Review 6.  The Interplay between Alpha-Synuclein Clearance and Spreading.

Authors:  Tomás Lopes da Fonseca; Anna Villar-Piqué; Tiago Fleming Outeiro
Journal:  Biomolecules       Date:  2015-04-14

7.  Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay.

Authors:  Wendy E Heywood; Daniela Galimberti; Emily Bliss; Ernestas Sirka; Ross W Paterson; Nadia K Magdalinou; Miryam Carecchio; Emma Reid; Amanda Heslegrave; Chiara Fenoglio; Elio Scarpini; Jonathan M Schott; Nick C Fox; John Hardy; Kailiash Bhatia; Kailash Bahtia; Simon Heales; Neil J Sebire; Henrik Zetterberg; Henrik Zetterburg; Kevin Mills
Journal:  Mol Neurodegener       Date:  2015-12-01       Impact factor: 14.195

Review 8.  The Concept of Prodromal Parkinson's Disease.

Authors:  Philipp Mahlknecht; Klaus Seppi; Werner Poewe
Journal:  J Parkinsons Dis       Date:  2015       Impact factor: 5.568

9.  Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease.

Authors:  Sara Hall; Yulia Surova; Annika Öhrfelt; Kaj Blennow; Henrik Zetterberg; Oskar Hansson
Journal:  Mov Disord       Date:  2016-02-16       Impact factor: 10.338

10.  The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer's disease.

Authors:  Daniel Twohig; Elena Rodriguez-Vieitez; Sigrid B Sando; Guro Berge; Camilla Lauridsen; Ina Møller; Gøril R Grøntvedt; Geir Bråthen; Kalicharan Patra; Guojun Bu; Tammie L S Benzinger; Celeste M Karch; Anne Fagan; John C Morris; Randall J Bateman; Agneta Nordberg; Linda R White; Henrietta M Nielsen
Journal:  Acta Neuropathol Commun       Date:  2018-11-26       Impact factor: 7.578
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.